Inhaled Ciclesonide for Outpatients With COVID19 (CONTAIN)
Ciclesonide Clinical Trial for COVID-19 Treatment
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Terminated
could not meet target enrolment
Other terminated trials from McGill University Health Centre/Research Institute of the McGill University Health Centre
Other COVID 19 trials with similar outcome
A PHASE2/PHASE3 clinical study on COVID 19, this trial is terminated or withdrawn. The trial is conducted by McGill University Health Centre/Research Institute of the McGill University Health Centre and has accumulated 8 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
May 2022 — Jul 2022 [monthly]
Terminated PHASE2_PHASE3
-
Sep 2021 — May 2022 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .